The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond

The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond

Abstract CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent, lecanemab, in mild cognitive impairment and mild dementia due to Alzheimer disease (AD). Lecanemab effectively reduced mean brain amyloid burden and...

Full description

Bibliographic Details
Main Authors: Rawan Tarawneh, Vernon S. Pankratz
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Alzheimer’s Research & Therapy
Subjects:
Lecanemab
Alzheimer disease
Clinical outcomes
Clinically meaningful change
Minimal clinically important difference
Online Access:https://doi.org/10.1186/s13195-024-01412-z

Internet

https://doi.org/10.1186/s13195-024-01412-z

Similar Items